Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
36
ORPEF Quote, Financials, Valuation and Earnings
Last price:
$6.6000
Seasonality move
:
-11.93%
Day range:
$6.6000 - $6.6000
52-week range:
$6.6000 - $14.2200
Dividend yield:
0%
P/E ratio:
1.15x
P/S ratio:
0.17x
P/B ratio:
0.59x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$1.1B
Revenue:
$6.1B
EPS (TTM):
$12.37
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Emeis SA has -- downside to fair value with a price target of -- per share.
ORPEF vs. S&P 500
-
Over the past 5 trading days, Emeis SA has overperformed the S&P 500 by 0.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Emeis SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Emeis SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Emeis SA reported revenues of --.
Earnings Growth
-
Emeis SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Emeis SA reported earnings per share of --.
Enterprise value:
5.2B
EV / Invested capital:
--
Price / LTM sales:
0.17x
EV / EBIT:
126.21x
EV / Revenue:
0.87x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.89x
Price / Operating cash flow:
2.79x
Enterprise value / EBITDA:
6.68x
Gross Profit (TTM):
$4.6B
Return On Assets:
10.28%
Net Income Margin (TTM):
27.05%
Return On Equity:
221.67%
Return On Invested Capital:
21.07%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2013-03-31 | 2014-03-31 | 2015-03-31 | 2014-03-31 | 2015-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $215M | $202.8M | |
| Gross Profit | -- | -- | -- | $62.6M | $55.5M | |
| Operating Income | -- | -- | -- | $35.4M | $25M | |
| EBITDA | -- | -- | -- | $51.2M | $40.1M | |
| Diluted EPS | -- | -- | -- | $0.59 | $0.48 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3B | $3.1B | $2.3B | $2.6B | -- | |
| Total Assets | $21.1B | $20.7B | $16B | $14.8B | -- | |
| Current Liabilities | $3.7B | $3.7B | $11.4B | $3.3B | -- | |
| Total Liabilities | $16.9B | $16.8B | $18B | $12.8B | -- | |
| Total Equity | $4.2B | $3.9B | -$2B | $2.1B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-09 | 2024-12-09 | 2024-12-09 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
ORPEF
Sector
Market Cap
$1.1B
$28.5M
Price % of 52-Week High
46.41%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.33%
1-Year Price Total Return
--
-21.18%
Beta (5-Year)
632.999
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.6000
200-day SMA
Sell
Level
$6.6762
Bollinger Bands (100)
Sell
Level
5.6824 - 7.8224
Chaikin Money Flow
Sell
Level
-359
20-day SMA
Sell
Level
$6.6000
Relative Strength Index (RSI14)
Sell
Level
48.1481
ADX Line
Sell
Level
5.0332
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$6.7524
MACD (12, 26)
Sell
Level
-0.0758
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-6.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.4083)
Sell
CA Score
(Annual)
Level (-1.9886)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.0398)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Emeis SA engages in the operation of geriatric healthcare facilities. It operates through the following geographical segments: France Benelux UK Ireland, Central Europe, Eastern Europe, Iberian Peninsula/Latin America, and Others. Its services include nursing homes, psychiatric care clinics, home care, and post-acute and rehabilitation clinics. The company was founded by Jean-Claude Marian in 1989 and is headquartered in Puteaux, France.
Stock Forecast FAQ
In the current month, ORPEF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ORPEF average analyst price target in the past 3 months is --.
-
Where Will Emeis SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Emeis SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Emeis SA?
Analysts are divided on their view about Emeis SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Emeis SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Emeis SA's Price Target?
The price target for Emeis SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ORPEF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Emeis SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ORPEF?
You can purchase shares of Emeis SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Emeis SA shares.
-
What Is The Emeis SA Share Price Today?
Emeis SA was last trading at $6.6000 per share. This represents the most recent stock quote for Emeis SA. Yesterday, Emeis SA closed at $6.6000 per share.
-
How To Buy Emeis SA Stock Online?
In order to purchase Emeis SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ORPEF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ORPEF
Sector
P/E ratio
1.15x
23.66x
PEG ratio
--
-0.01x
P/B ratio
0.59x
1.82x
Price / LTM sales
0.17x
1.61x
Growth Metrics
ORPEF
Sector
Revenue growth
--
4.8%
Earnings growth
--
11.11%
Revenue (5-year growth)
7.81%
6.45%
Earnings forecast
--
-$0.20
Profitability
ORPEF
Sector
Profitability FY 2024
$16M
$3.6M
Return on invested capital
21.07%
-31.15%
Return on assets
10.28%
-27.72%
Return on equity
221.67%
-36.72%
Earnings Date
Last Earnings Date
Sep
30
Next Earnings Date
Apr
15
Estimated Next Earnings Date
Dec
30
Balance Sheet
ORPEF
Sector
Total cash
$699.8M
$27M
Short term investments
--
$25.7M
Total assets
$13.9B
$79.7M
Long term debt
$4.8B
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.26% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is up 2.34% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.55% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
